<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074815</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008097</org_study_id>
    <secondary_id>R01MH055121</secondary_id>
    <secondary_id>DSIR 84-CTM</secondary_id>
    <nct_id>NCT00074815</nct_id>
  </id_info>
  <brief_title>Treatment of Obsessive Compulsive Disorder in Children</brief_title>
  <official_title>Treatment of Pediatric OCD for SRI Partial Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether cognitive behavioral therapy delivered by either
      psychologists or psychiatrists can improve the effectiveness of serotonin reuptake inhibitor
      treatment in children with obsessive compulsive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vast majority of children with obsessive compulsive disorder (OCD) are given serotonin
      reuptake inhibitor (SRI) drugs as initial treatment. However, recommended doses of these
      medications leave many children with clinically significant residual symptoms. Health care
      experts typically recommend augmenting SRI treatment with cognitive behavioral therapy (CBT),
      yet this recommendation is seldom followed. This study will contrast two CBT augmentation
      strategies to continued medication management alone: CBT administered by a psychologist and
      instructional CBT (I-CBT)administered by a psychiatrist in the context of ongoing medication
      management.

      All patients in the trial will be eligible to receive a full course of CBT by study end.
      Participants in this study will be randomly assigned to receive CBT, I-CBT or continued
      medication management. All participants will continue their SRI treatment for 12 weeks. After
      the 12-week treatment period, participants who received I-CBT or medication management alone
      and who remain symptomatic will be given CBT as will participants who are asymptomatic but
      relapse within 6 months after treatment. Assessments will be conducted at Weeks 0, 4, 8, and
      12. Follow-up assessments will be conducted at 3 and 6 months post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)</measure>
    <time_frame>Measured at baseline and Week 12.</time_frame>
    <description>OCD symptom severity was measured using the CY-BOCS, an interviewer-rated instrument that assess obsessions and compulsions separately on time consumed, distress, interference, degree of resistance, and control; it yields separate severity scores for obsessions and for compulsions (0 - 20), and a composite symptom severity score (0 to 40).
Consistent with signal detection analyses examining the optimal criterion for treatment response, a CY-BOCS reduction of 30% or more from baseline to week 12 was used as the criterion for RESPONSE and was the primary dichotomous outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child Obsessive -Compulsive Impact Scale (COIS)</measure>
    <time_frame>Measured at baseline; Weeks 4, 8, and 12; and Months 3 and 6 of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Depression Inventory</measure>
    <time_frame>Measured at baseline; Weeks 4, 8, and 12; and Months 3 and 6 of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Adverse Event Rating Scale (PAERS)</measure>
    <time_frame>Measured at baseline; Weeks 4, 8, and 12; and Months 3 and 6 of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>MedMgmt+CBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following interventions: 1)SRI medication management with a psychiatrist plus, 2) cognitive behavioral therapy with a psychologist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MedMgmt+I-CBT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following interventions 1)SRI medication management plus, 2) instructional cognitive behavioral therapy. Both of these will be implemented by the same psychiatrist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MedMgmt Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the intervention SRI medication management with a psychiatrist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serotonin reuptake inhibitors management</intervention_name>
    <description>Participants are maintained on their optimized dose of SRI for OCD symptoms (see &quot;Other Names&quot; section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI.</description>
    <arm_group_label>MedMgmt+CBT</arm_group_label>
    <arm_group_label>MedMgmt+I-CBT</arm_group_label>
    <arm_group_label>MedMgmt Only</arm_group_label>
    <other_name>Drug Name with Minimum-Maximum Dosage</other_name>
    <other_name>Citalopram (Celexa)10-60;</other_name>
    <other_name>Escitalopram (Lexapro)5-30;</other_name>
    <other_name>Fluoxetine (Prozac) 10-60;</other_name>
    <other_name>Fluvoxamine (Luvox)25-300;</other_name>
    <other_name>Paroxetine (Paxil)10-50;</other_name>
    <other_name>Paroxetine-CR (Paxil)10-50;</other_name>
    <other_name>Clomipramine (Anafranil)25-200;</other_name>
    <other_name>Sertraline (Zoloft) 25-200;</other_name>
    <other_name>Venlafaxine (Effexor)25-225;</other_name>
    <other_name>Venlafaxine XR (Effexor)37.5-225;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral therapy by a psychologist</intervention_name>
    <description>CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.</description>
    <arm_group_label>MedMgmt+CBT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Instructional cognitive behavioral therapy by a psychiatrist</intervention_name>
    <description>The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor &quot;best practice&quot; treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy.</description>
    <arm_group_label>MedMgmt+I-CBT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV Diagnosis of obsessive compulsive disorder

          -  CYBOCS total score greater than 16

        Exclusion Criteria:

          -  Other primary or co-primary psychiatric disorder

          -  Pervasive developmental disorder or disorders, including Asperger's Syndrome

          -  Thought disorder

          -  Prior failed trial of cognitive-behavioral therapy

          -  Has pediatric autoimmune neuropsychiatric disorders associated with streptococcus
             (PANDAS) or maintenance antibiotic for obsessive-compulsive disorder

          -  Mental retardation

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John S March, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Child and Family Study Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, The Center for the Treatment and Study of Anxiety</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Franklin ME, Sapyta J, Freeman JB, Khanna M, Compton S, Almirall D, Moore P, Choate-Summers M, Garcia A, Edson AL, Foa EB, March JS. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA. 2011 Sep 21;306(11):1224-32. doi: 10.1001/jama.2011.1344. Erratum in: JAMA. 2012 Apr 25;307(16):1694.</citation>
    <PMID>21934055</PMID>
  </results_reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2003</study_first_submitted>
  <study_first_submitted_qc>December 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2003</study_first_posted>
  <results_first_submitted>November 15, 2012</results_first_submitted>
  <results_first_submitted_qc>January 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2013</results_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Child</keyword>
  <keyword>Adolescent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Clomipramine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MM + CBT</title>
          <description>Participants will receive medication management plus cognitive behavioral therapy with a psychologist</description>
        </group>
        <group group_id="P2">
          <title>MM + ICBT</title>
          <description>Participants will receive medication management plus instructional cognitive behavioral therapy with a psychiatrist</description>
        </group>
        <group group_id="P3">
          <title>MM Only</title>
          <description>Participants will receive medication management only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MM + CBT</title>
          <description>Participants will receive medication management plus cognitive behavioral therapy with a psychologist</description>
        </group>
        <group group_id="B2">
          <title>MM + ICBT</title>
          <description>Participants will receive medication management plus instructional cognitive behavioral therapy with a psychiatrist</description>
        </group>
        <group group_id="B3">
          <title>MM Only</title>
          <description>Participants will receive medication management only</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.71" spread="2.88"/>
                    <measurement group_id="B2" value="13.76" spread="2.72"/>
                    <measurement group_id="B3" value="14.34" spread="2.51"/>
                    <measurement group_id="B4" value="13.6" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)</title>
        <description>OCD symptom severity was measured using the CY-BOCS, an interviewer-rated instrument that assess obsessions and compulsions separately on time consumed, distress, interference, degree of resistance, and control; it yields separate severity scores for obsessions and for compulsions (0 – 20), and a composite symptom severity score (0 to 40).
Consistent with signal detection analyses examining the optimal criterion for treatment response, a CY-BOCS reduction of 30% or more from baseline to week 12 was used as the criterion for RESPONSE and was the primary dichotomous outcome measure.</description>
        <time_frame>Measured at baseline and Week 12.</time_frame>
        <population>Intent to treat (all included)</population>
        <group_list>
          <group group_id="O1">
            <title>MM + CBT</title>
            <description>Participants will receive medication management plus cognitive behavioral therapy with a psychologist</description>
          </group>
          <group group_id="O2">
            <title>MM + ICBT</title>
            <description>Participants will receive medication management plus instructional cognitive behavioral therapy with a psychiatrist</description>
          </group>
          <group group_id="O3">
            <title>MM Only</title>
            <description>Participants will receive medication management only</description>
          </group>
        </group_list>
        <measure>
          <title>Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)</title>
          <description>OCD symptom severity was measured using the CY-BOCS, an interviewer-rated instrument that assess obsessions and compulsions separately on time consumed, distress, interference, degree of resistance, and control; it yields separate severity scores for obsessions and for compulsions (0 – 20), and a composite symptom severity score (0 to 40).
Consistent with signal detection analyses examining the optimal criterion for treatment response, a CY-BOCS reduction of 30% or more from baseline to week 12 was used as the criterion for RESPONSE and was the primary dichotomous outcome measure.</description>
          <population>Intent to treat (all included)</population>
          <units>Proportion of Participants with RESPONSE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.54" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.34" lower_limit="0.18" upper_limit="0.50"/>
                    <measurement group_id="O3" value="0.30" lower_limit="0.15" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Child Obsessive -Compulsive Impact Scale (COIS)</title>
        <time_frame>Measured at baseline; Weeks 4, 8, and 12; and Months 3 and 6 of follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Child Depression Inventory</title>
        <time_frame>Measured at baseline; Weeks 4, 8, and 12; and Months 3 and 6 of follow-up</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pediatric Adverse Event Rating Scale (PAERS)</title>
        <time_frame>Measured at baseline; Weeks 4, 8, and 12; and Months 3 and 6 of follow-up</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MM + CBT</title>
          <description>Participants will receive medication management plus cognitive behavioral therapy with a psychologist</description>
        </group>
        <group group_id="E2">
          <title>MM + ICBT</title>
          <description>Participants will receive medication management plus instructional cognitive behavioral therapy with a psychiatrist</description>
        </group>
        <group group_id="E3">
          <title>MM Only</title>
          <description>Participants will receive medication management only</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Suicide Attempt</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt that led to hospitalization and changes to medication and therapy</sub_title>
                <description>Attempt led to premature termination of treatment protocol (i.e., additional treatment outside of randomized treatment protocol). Stopped OCD treatment and began treating subject's comorbid depression.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title vocab="Suicidal Thougths">Suicidal Thoughts due to school difficulties</sub_title>
                <description>In last protocol session, subject reported suicidal thoughts due to teasing by classmates. Given the context in which these thoughts arose (social difficulties at school), this serious adverse event was determined to be unrelated to treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Sapyta, PhD</name_or_title>
      <organization>Duke University School of Medicine</organization>
      <phone>919-668-0069</phone>
      <email>jeffrey.sapyta@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

